Item 1.01. Entry into a Material Definitive Agreement.
On January 25, 2022, Bolt Biotherapeutics, Inc. (the "Company") entered into an
amended and restated supply agreement with EirGenix, Inc. (the "Amended Supply
Agreement"), which amends the original supply agreement with EirGenix, Inc.
("EirGenix") dated March 10, 2019, pursuant to which EirGenix agreed to supply
to the Company, on a non-exclusive basis, bulk drug substance of EG12014, its
monoclonal antibody being developed as a biosimilar of trastuzumab, which the
Company uses in the manufacture of its BDC-1001 HER2 Boltbody ISAC. The Amended
Supply Agreement, among other things, requires the constitution of a joint
steering committee, amends the forecasting schedules and methods of addressing
any order delays or cancellations, and adjusts supply pricing based on the scale
of production. The remaining terms and conditions under the Amended Supply
Agreement remained substantially the same as the original supply agreement.
Under the Amended Supply Agreement, EirGenix provides the Company with its
regulatory data package containing the sections of chemistry, manufacturing and
control of drug substance EG12014 to facilitate the Company's development and
commercialization efforts, and the Company is required to make milestone
payments to EirGenix up to an aggregate of $2.0 million based upon achievement
of certain regulatory milestones by the Company's HER2 Boltbody ISAC. The
agreement will remain in effect as long as the Company, or any of its affiliates
or licensees, continue to pursue the development or commercialization of any
Boltbody ISAC containing drug substance EG12014, unless earlier terminated in
accordance with the terms of the Amended Supply Agreement.
The foregoing description of the material terms of the Amended Supply Agreement
is qualified in its entirety by reference to the full text of the Amended Supply
Agreement, which the Company intends to file as an exhibit to its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022, to be filed with the
Securities and Exchange Commission.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses